Astrazeneca (AZN) Accounts Payables (2009 - 2026)

Astrazeneca (AZN) has reported Accounts Payables for 18 consecutive years, with -$22.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables changed 0.17% year-over-year to -$22.5 billion; the TTM figure through Mar 2026 stood at -$22.5 billion (changed 0.17% YoY), while the FY2025 annual figure was -$25.3 billion, down 212.53% from the prior year.
• Accounts Payables came in at -$22.5 billion for Q1 2026 at Astrazeneca, up from -$25.3 billion in the prior quarter.
• The five-year high for Accounts Payables was $22.5 billion in Q4 2024, with the low at -$25.3 billion in Q4 2025.
• Average Accounts Payables over 5 years is -$14.5 billion, with a median of -$19.7 billion recorded in 2023.
• Across the five-year window, Accounts Payables jumped 777.41% in 2023 and sank 212.53% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $2.6 billion in 2022, then surged by 777.41% to $22.4 billion in 2023, then gained by 0.41% to $22.5 billion in 2024, then tumbled by 212.53% to -$25.3 billion in 2025, then gained by 10.98% to -$22.5 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered -$22.5 billion, -$25.3 billion, and -$25.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.